Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial

MLA

Manjaly Thomas, Zita-Rose, et al. “Alternate Aerosol and Systemic Immunisation with a Recombinant Viral Vector for Tuberculosis, MVA85A: A Phase I Randomised Controlled Trial.” PLoS Medicine, vol. 16, no. 4, Apr. 2019, p. e1002790. EBSCOhost, https://doi.org/10.1371/journal.pmed.1002790.

APA

Manjaly Thomas, Z.-R., Satti, I., Marshall, J. L., Harris, S. A., Lopez Ramon, R., Hamidi, A., Minhinnick, A., Riste, M., Stockdale, L., Lawrie, A. M., Vermaak, S., Wilkie, M., Bettinson, H., & McShane, H. (2019). Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial. PLoS Medicine, 16(4), e1002790. https://doi.org/10.1371/journal.pmed.1002790

Chicago

Manjaly Thomas, Zita-Rose, Iman Satti, Julia L. Marshall, Stephanie A. Harris, Raquel Lopez Ramon, Ali Hamidi, Alice Minhinnick, et al. 2019. “Alternate Aerosol and Systemic Immunisation with a Recombinant Viral Vector for Tuberculosis, MVA85A: A Phase I Randomised Controlled Trial.” PLoS Medicine 16 (4): e1002790. doi:10.1371/journal.pmed.1002790.